Stephen V Liu: Taletrectinib and zidesamtinib promise to move the field of ROS1 NSCLC by addressing resistance and safety

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:

“Dr. Yasir Elamin at TexasLung25 brings us up to speed on ROS1 NSCLC – highlighting resistance and safety.

Emerging agents like taletrectinib and zidesamtinib promise to move the field even further!”